Mirum Pharmaceuticals (MIRM) Finished Goods (2021 - 2026)

Mirum Pharmaceuticals' Finished Goods history runs 6 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• In Q1 2026, Finished Goods fell 4.39% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $3.4 million (down 4.39% YoY), while the FY2025 annual figure was $3.5 million, up 7.06% from the prior year.
• Finished Goods was $3.4 million for Q1 2026 at Mirum Pharmaceuticals, down from $3.5 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $11.3 million in Q3 2023 to a low of $129000.0 in Q1 2023.
• Historically, Finished Goods has averaged $3.6 million across 5 years, with a median of $3.4 million in 2026.
• The sharpest annual moves came in 2023 and 2024: Finished Goods surged 6200.0% in 2023, then slumped 65.22% in 2024.
• A 5-year view of Finished Goods shows it stood at $214000.0 in 2022, then surged by 4311.68% to $9.4 million in 2023, then plunged by 65.22% to $3.3 million in 2024, then climbed by 7.06% to $3.5 million in 2025, then dropped by 2.79% to $3.4 million in 2026.
• The last three Finished Goods figures came in at $3.4 million (Q1 2026), $3.5 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.